BusinessNeos Therapeutics Launches Adzenys ER™ (amphetamine) Extended-Release Oral Suspension in U.S. for the Treatment of ADHD in Patients 6 Years and OlderBy Nasdaq OMXFeb 26, 2018, 1:00 PM UTC
BusinessNeos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and OlderBy Nasdaq OMXSep 15, 2017, 8:39 PM UTC
BusinessNeos Therapeutics to Participate in Three September ConferencesBy Nasdaq OMXAug 30, 2017, 11:30 AM UTC
BusinessNeos Therapeutics Announces Proposed Offering of Common StockBy Nasdaq OMXJun 26, 2017, 8:02 PM UTC
BusinessNeos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years OldBy Nasdaq OMXJun 20, 2017, 1:47 AM UTC
BusinessNeos Therapeutics to Present at the JMP Securities 2017 Life Sciences ConferenceBy Nasdaq OMXJun 14, 2017, 11:30 AM UTC
BusinessNeos Therapeutics to Present at Jefferies 2017 Global Healthcare ConferenceBy Nasdaq OMXMay 30, 2017, 11:34 AM UTC
BusinessNeos Therapeutics to Present at Jefferies 2017 Global Healthcare ConferenceBy Nasdaq OMXMay 30, 2017, 11:33 AM UTC
